Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial

The DCGI has approved the company's remdesivir 100 mg per vial for restricted emergency use in India as part of the regulator's accelerated approval process to address urgent, unmet needs amid the evolving COVID-19 pandemic, Mylan said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2VRpkvN
via IFTTT